Opinion
Video
Author(s):
Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.
Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Advancements With Combination Therapies in RCC Usher in New Questions
Kitko and Patel Emphasize the Importance of GVHD Research and Awareness
Lenvatinib Plus Pembrolizumab Delays Tumor Progression in All Organs vs Sunitinib in Advanced RCC
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC
Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML